FDA Approves New Combination Therapy for Relapsed Multiple Myeloma

Bristol-Myers Squibb's iberdomide, combined with daratumumab and dexamethasone, has received FDA approval for adults with relapsed or refractory multiple myeloma after at least one prior therapy. This approval is notable as it's the first in this setting based on minimal residual disease (MRD)-negative complete response data, offering a new treatment option for patients.